BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Sarcomas AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4
788 results:

  • 1.
    de Traux de Wardin H; Dermawan JK; Vanoli F; Jiang SC; Singer S; Chi P; Tap W; Wexler LH; Antonescu CR
    JCO Precis Oncol; 2024 Apr; 8():e2300597. PubMed ID: 38603649
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Primary hepatic pleomorphic liposarcoma: Case report and literature review.
    Redrobán L; Lara-Endara J; Montalvo N; Armijos C; Rodríguez-Suárez J; Serpa F
    Rev Esp Patol; 2024; 57(2):128-132. PubMed ID: 38599733
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Atypical Spindle Cell/Pleomorphic Lipomatous Tumor With Sarcomatous Transformation: Clinicopathologic and Molecular Analysis of 4 Cases.
    Perret R; Charville GW; Alame M; Rebier F; Soubeyran I; Gross JM; Graham D; Green DC; Kerr DA; Khan WA; Cloutier JM
    Mod Pathol; 2024 Apr; 37(4):100454. PubMed ID: 38417627
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. NRF2 Activation in Trp53;p16-deficient Mice Drives Oral Squamous Cell Carcinoma.
    Hamad SH; Sellers RS; Wamsley N; Zolkind P; Schrank TP; Major MB; Weissman BE
    Cancer Res Commun; 2024 Feb; 4(2):487-495. PubMed ID: 38335300
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations.
    Klubíčková N; Dermawan JK; Mosaieby E; Martínek P; Vaněček T; Hájková V; Ptáková N; Grossmann P; Šteiner P; Švajdler M; Kinkor Z; Michalová K; Szepe P; Plank L; Hederová S; Kolenová A; Spasov NJ; Kosemehmetoglu K; Pažanin L; Špůrková Z; Baník M; Baumruk L; Meyer A; Kalmykova A; Koshyk O; Michal M; Michal M
    J Pathol; 2024 May; 263(1):61-73. PubMed ID: 38332737
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
    Wang WN; Liu XT; Liang YM
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
    [No Abstract]    [Full Text] [Related]  

  • 7. Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma.
    Lorenzo-Guerra SL; Codina-Martínez H; Suárez-Fernández L; Cabal VN; García-Marín R; Riobello C; Vivanco B; Blanco-Lorenzo V; Sánchez-Fernández P; López F; Llorente JL; Hermsen MA
    Cells; 2023 Dec; 13(1):. PubMed ID: 38201285
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Establishment and Characterization of Cell Lines from Canine Metastatic Osteosarcoma.
    Yang YT; Engleberg AI; Yuzbasiyan-Gurkan V
    Cells; 2023 Dec; 13(1):. PubMed ID: 38201229
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population.
    Patrizi S; Miele E; Falcone L; Vallese S; Rossi S; Barresi S; Giovannoni I; Pedace L; Nardini C; Masier I; Abballe L; Cacchione A; Russo I; Di Giannatale A; Di Ruscio V; Salgado CM; Mastronuzzi A; Ciolfi A; Tartaglia M; Milano GM; Locatelli F; Alaggio R
    Clin Epigenetics; 2024 Jan; 16(1):9. PubMed ID: 38178234
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Comparative analysis of EZH2, p16 and p53 expression in uterine carcinosarcomas.
    Makk E; Bohonyi N; Oszter A; Éles K; Tornóczky T; Tóth A; Kálmán E; Kovács K
    Pathol Oncol Res; 2023; 29():1611547. PubMed ID: 38146588
    [No Abstract]    [Full Text] [Related]  

  • 11. Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.
    Mitchell DK; Burgess B; White EE; Smith AE; Sierra Potchanant EA; Mang H; Hickey BE; Lu Q; Qian S; Bessler W; Li X; Jiang L; Brewster K; Temm C; Horvai A; Albright EA; Fishel ML; Pratilas CA; Angus SP; Clapp DW; Rhodes SD
    Clin Cancer Res; 2024 Mar; 30(5):1038-1053. PubMed ID: 38127282
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Primary cutaneous SMARCA4-deficient undifferentiated malignant neoplasm: A rare case report and literature review.
    Gumusgoz E; Graham BS; Hosler GA
    J Cutan Pathol; 2024 Apr; 51(4):262-266. PubMed ID: 38124373
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Spindle cell rhabdomyosarcomas: With TFCP2 rearrangements, and novel EWSR1::ZBTB41 and PLOD2::RBM6 gene fusions. A study of five cases and review of the literature.
    Bradová M; Mosaieby E; Michal M; Vaněček T; Ing SK; Grossmann P; Koshyk O; Kinkor Z; Laciok Š; Nemcová A; Straka Ľ; Farkas M; Michal M; Švajdler M
    Histopathology; 2024 Apr; 84(5):776-793. PubMed ID: 38114270
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Acantholytic squamous cell carcinoma mimicking epithelioid angiosarcoma: A diagnostic challenge by cytology.
    Taweevisit M; Sutthiruangwong P; Thorner PS
    Diagn Cytopathol; 2024 Mar; 52(3):E76-E79. PubMed ID: 38069674
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. sarcomas Harboring EWSR1::PATZ1 Fusions: A Clinicopathologic Study of 17 Cases.
    Dehner CA; Torres-Mora J; Gupta S; Kipp BR; Halling KC; Chen S; Warmke LM; Michal M; Alani A; Yu W; Kovacs K; Obeidin F; Iwenofu OH; Satturwar S; Meis JM; Folpe AL
    Mod Pathol; 2024 Feb; 37(2):100400. PubMed ID: 38043789
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Sarcomatoid mesothelioma diagnosed in a patient with mesothelioma in situ: a case report on morphologic differences after 9-month interval with details analysis of cytology in early-stage mesothelioma.
    Yoshida M; Jimbo N; Tsukamoto R; Itoh T; Kawahara K; Mitsui S; Tanaka Y; Maniwa Y
    Diagn Pathol; 2023 Nov; 18(1):126. PubMed ID: 38017544
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The oncogenic fusion protein TAZ::CAMTA1 promotes genomic instability and senescence through hypertranscription.
    Neil E; Paredes R; Pooley O; Rubin B; Kouskoff V
    Commun Biol; 2023 Nov; 6(1):1174. PubMed ID: 37980390
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
    Searcy MB; Larsen RK; Stevens BT; Zhang Y; Jin H; Drummond CJ; Langdon CG; Gadek KE; Vuong K; Reed KB; Garcia MR; Xu B; Kimbrough DW; Adkins GE; Djekidel N; Porter SN; Schreiner PA; Pruett-Miller SM; Abraham BJ; Rehg JE; Hatley ME
    Nat Commun; 2023 Nov; 14(1):7291. PubMed ID: 37968277
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study.
    Phadnis S; Wang X; Daw NC; Herzog CE; Subbiah IM; Zaky W; Gouda MA; Morani AC; Amini B; Harrison DJ; Piha-Paul SA; Meric-Bernstam F; Gorlick R; Schwartz CL; Subbiah V
    ESMO Open; 2023 Dec; 8(6):101609. PubMed ID: 37879233
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ cdkn2a.
    Martin-Broto J; Martinez-Garcia J; Moura DS; Redondo A; Gutierrez A; Lopez-Pousa A; Martinez-Trufero J; Sevilla I; Diaz-Beveridge R; Solis-Hernandez MP; Carnero A; Perez M; Marcilla D; Garcia-Foncillas J; Romero P; Fernandez-Jara J; Lopez-Lopez D; Arribas I; Hindi N
    Signal Transduct Target Ther; 2023 Oct; 8(1):405. PubMed ID: 37875500
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 40.